Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric carboxymaltose - Vifor

Drug Profile

Ferric carboxymaltose - Vifor

Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vifor
  • Developer American Regent; Vifor; Zeria
  • Class Antianaemics; Cardiovascular therapies; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Chronic heart failure; Restless legs syndrome

Most Recent Events

  • 06 Nov 2019 Luitpold Pharmaceuticals completes a phase III trial in Iron deficiency anaemia (related to cancer) in USA, Hungary, Poland, Bulgaria (NCT02453334)
  • 08 Aug 2019 Registered for Iron deficiency anaemia in Japan (IV)
  • 14 Mar 2019 Vifor Pharma announces intention to launch ferric carboxymaltose for Iron deficiency anaemia in Japan in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top